Clinical Trials
76
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (59 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: PlaceboDrug: (Part B) MKND-201Drug: (Part A) MKND-201
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT06532942
- Locations
- 🇺🇸
Flourish Research, San Antonio, Texas, United States
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
- Conditions
- Treatment Refractory MAC Lung DiseaseMAC Lung DiseaseMycobacterium Infections, Nontuberculous
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 234
- Registration Number
- NCT06418711
- Locations
- 🇺🇸
University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
🇺🇸University of California San Francisco Fresno, Fresno, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 141
- Registration Number
- NCT05904743
- Locations
- 🇺🇸
Loma Linda University-Diabetes Treatment Center, Loma Linda, California, United States
🇺🇸Sansum Diabetes Research, Santa Barbara, California, United States
🇺🇸Barbara Davis Center, Aurora, Colorado, United States
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
- Conditions
- Type 1 Diabetes
- Interventions
- Device: Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 33
- Registration Number
- NCT05243628
- Locations
- 🇺🇸
Diabetes Treatment Center, Loma Linda University, Loma Linda, California, United States
🇺🇸Texas Diabetes and Endocrinology, Austin, Texas, United States
Afrezza® INHALE-1 Study in Pediatrics
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 319
- Registration Number
- NCT04974528
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
MannKind Appoints Dr. Ajay Ahuja as Chief Medical Officer to Advance Inhaled Therapeutics Pipeline
MannKind Corporation has appointed Dr. Ajay Ahuja as Chief Medical Officer, bringing over two decades of biopharmaceutical leadership experience to advance the company's inhaled therapeutics pipeline.
MannKind Acquires scPharmaceuticals for Up to $360M to Expand Cardiorenal Portfolio
MannKind Corporation announced the acquisition of scPharmaceuticals for up to $360 million, marking its strategic expansion into cardiorenal medicine with FUROSCIX as the key asset.
MannKind Secures $500 Million Strategic Financing from Blackstone to Advance Inhaled Therapeutics Pipeline
MannKind Corporation has secured up to $500 million in non-dilutive financing from Blackstone, with $75 million available immediately at closing.
MannKind Prepares to Present Pediatric Inhaled Insulin Data at ADA Scientific Sessions
MannKind Corporation will showcase results from its Phase 3 INHALE-1 clinical trial of Afrezza inhaled insulin in children and adolescents aged 4-17 at the American Diabetes Association's 85th Scientific Sessions in Chicago.
Inhaled Insulin Shows Promising Results in Type 1 Diabetes Management Over 30 Weeks
INHALE-3 trial data reveals that 74% of adults with type 1 diabetes increased their technosphere insulin (Afrezza) dose by more than 4 units over 30 weeks, with total daily doses rising from 36 to 52 units.
MannKind Initiates Phase 3 Trial of Clofazimine Inhalation Suspension for NTM Lung Disease
MannKind Corporation has started its Phase 3 ICoN-1 trial to assess Clofazimine Inhalation Suspension for treating nontuberculous mycobacterial (NTM) lung disease.